Breaking News Instant updates and real-time market news.

CPRX

Catalyst Pharmaceuticals

$3.14

0.44 (16.30%)

06:05
05/13/19
05/13
06:05
05/13/19
06:05

Catalyst Pharmaceuticals reports Q1 EPS (1c), may not compare to consensus (13c)

Reports Q1 revenue $12.4M, may not compare to consensus $1.6M. "The first quarter of this year was very critical for us, as we became a fully-integrated biopharmaceutical company with the commercial launch of Firdapse," said Patrick McEnany, Chairman and CEO of Catalyst Pharmaceuticals. "We are pleased that the Firdapse launch is off to an excellent start and while it is still early, with much work to be done, it is especially gratifying to see the number of patients that were previously naive to any form of amifampridine that are now being effectively treated with Firdapse. We continue to be motivated by the very positive response that we are receiving from patients and healthcare providers. Lastly, we continue to make progress in clinical development of our robust pipeline of other potential indications for Firdapse."

  • 13

    May

  • 23

    May

CPRX Catalyst Pharmaceuticals
$3.14

0.44 (16.30%)

03/19/19
PIPR
03/19/19
NO CHANGE
Target $7.5
PIPR
Overweight
Catalyst comments point toward strong Firdapse launch, says Piper Jaffray
Shares of Catalyst Pharmaceuticals are trading higher after the company's Q4 earnings call and comments from management that point toward a strong Firdapse launch, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. Accrual of former EAP patients onto Catalyst Pathways has been quicker than expected and payer interactions appear to be progressing nicely, adds the analyst. He views his $41.0M 2019 sales estimate as "readily achievable" and maintains an Overweight rating on Catalyst Pharmaceuticals with a $7.50 price target.
03/19/19
HCWC
03/19/19
NO CHANGE
HCWC
Catalyst's initial launch of Firdapse 'strong,' says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $9 price target on Catalyst Pharmaceuticals, saying the initial look at the Firdapse commercial launch suggests "healthy momentum" and "strong execution" on the part of the company. The analyst also noted that Firdapse is also being investigated in two Phase 3 trials for the treatment of anti-MuSK antibody positive myasthenia gravis and congenital myasthenic syndromes, with both trials planned to read out in the second half of 2019.
05/06/19
PIPR
05/06/19
NO CHANGE
Target $7.5
PIPR
Overweight
Ruzurgi approval to pressure Catalyst Pharmaceuticals, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro kept his Overweight rating and $7.50 price target on Catalyst Pharmaceuticals but warned that the stock could come under pressure after the FDA's "unexpected" approval of Jacobus' amifampridine, or Ruzurgi, for the treatment of pediatric LEMS patients. Shares of Catalyst Pharmaceuticals were down over 41% after hours, and the analyst expressed uncertainty over whether the company's Firdapse would be able to maintain the orphan drug price point set at launch. Catanzaro expects the management of Catalyst Pharmaceuticals to comment on the development.
05/07/19
CANT
05/07/19
NO CHANGE
Target $10
CANT
Overweight
Jacobus approval should not impact Catalyst's Firdapse, says Cantor Fitzgerald
The FDA last night approved private company Jacobus' Ruzurgi for the treatment of Lambert-Eaton myasthenic syndrome in patients six to less than 17 years of age, Cantor Fitzgerald analyst Charles Duncan tells investors in a research note. This is the first drug approved for pediatric LEMS, the analyst points out. Catalyst Pharmaceuticals' slightly different salt form of amifampridine, marketed as Firdapse, was the first drug approved for LEMS, but for adults only, he notes. The analyst does not see the approval of Ruzurgi as having a large impact in Firdapse's market potential. He estimates that the pediatric population consists of less than 5% of the prevalent LEMS population. Duncan reiterates an Overweight rating on Catalyst shares with a $10 price target.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.